Price movement over the last 24 hours
YieldMax AMD Option Income Strategy ETF vs Nuwellis Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $54.39, while Nuwellis Inc trades at $3.11 (market cap $1.10M). The key difference: YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| AMDY | NUWE | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $59.52 | $558.26 |
52-Week Low | $29.80 | $2.87 |
Market Cap | — | $1.10M |
Enterprise Value | — | -$713.47K |
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $55.56, up 2.04% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong weekly dividend distributions but lacks traditional valuation metrics. Recent news highlights its high-yield strategy and associated risks of NAV erosion, with support at $54 and resistance at $56.
The outlook is mixed: high income appeals, but structural risks and analyst caution suggest volatility. Investors must weigh yield sustainability against potential capital depreciation, with entry timing critical for long-term viability.
NUWE trades at $3.04, up 5.56% today, but faces bearish technical signals with oversold RSI readings. The company reported a net loss of $17.52M in 2025 with negative margins, though recent earnings beat expectations in two of the last three quarters. A reverse stock split was executed in June 2026, and new CEO Mike McCormick is focusing on pediatric market expansion.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and recent FDA engagement offer potential growth. Risks include financial sustainability and competitive pressures. Analyst sentiment is split evenly between Buy and Hold.
Trailing returns across standard periods
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →